These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 25767210)

  • 1. Homologous Mutation to Human BRAF V600E Is Common in Naturally Occurring Canine Bladder Cancer--Evidence for a Relevant Model System and Urine-Based Diagnostic Test.
    Decker B; Parker HG; Dhawan D; Kwon EM; Karlins E; Davis BW; Ramos-Vara JA; Bonney PL; McNiel EA; Knapp DW; Ostrander EA
    Mol Cancer Res; 2015 Jun; 13(6):993-1002. PubMed ID: 25767210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identifying the ErbB/MAPK Signaling Cascade as a Therapeutic Target in Canine Bladder Cancer.
    Cronise KE; Hernandez BG; Gustafson DL; Duval DL
    Mol Pharmacol; 2019 Jul; 96(1):36-46. PubMed ID: 31048548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Establishment of Canine Transitional Cell Carcinoma Cell Lines Harboring BRAF V595E Mutation as a Therapeutic Target.
    Jung H; Bae K; Lee JY; Kim JH; Han HJ; Yoon HY; Yoon KA
    Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effective detection of BRAF
    Aeschlimann L; Kehl A; Guscetti F; Posthaus C; Aupperle-Lellbach H; Rottenberg S; de Brot S
    Vet Comp Oncol; 2024 Jun; 22(2):295-302. PubMed ID: 38659202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Whole exome sequencing analysis of canine urothelial carcinomas without BRAF V595E mutation: Short in-frame deletions in BRAF and MAP2K1 suggest alternative mechanisms for MAPK pathway disruption.
    Thomas R; Wiley CA; Droste EL; Robertson J; Inman BA; Breen M
    PLoS Genet; 2023 Apr; 19(4):e1010575. PubMed ID: 37079639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRAF Mutations in Canine Cancers.
    Mochizuki H; Kennedy K; Shapiro SG; Breen M
    PLoS One; 2015; 10(6):e0129534. PubMed ID: 26053201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Diagnostic value of the BRAF variant V595E in urine samples, smears and biopsies from canine transitional cell carcinoma].
    Aupperle-Lellbach H; Grassinger J; Hohloch C; Kehl A; Pantke P
    Tierarztl Prax Ausg K Kleintiere Heimtiere; 2018 Oct; 46(5):289-295. PubMed ID: 30541168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RNAseq expression patterns of canine invasive urothelial carcinoma reveal two distinct tumor clusters and shared regions of dysregulation with human bladder tumors.
    Parker HG; Dhawan D; Harris AC; Ramos-Vara JA; Davis BW; Knapp DW; Ostrander EA
    BMC Cancer; 2020 Mar; 20(1):251. PubMed ID: 32209086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Canine invasive transitional cell carcinoma cell lines: in vitro tools to complement a relevant animal model of invasive urinary bladder cancer.
    Dhawan D; Ramos-Vara JA; Stewart JC; Zheng R; Knapp DW
    Urol Oncol; 2009; 27(3):284-92. PubMed ID: 18562222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of BRAF Mutation in Urine DNA as a Molecular Diagnostic for Canine Urothelial and Prostatic Carcinoma.
    Mochizuki H; Shapiro SG; Breen M
    PLoS One; 2015; 10(12):e0144170. PubMed ID: 26649430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRAF
    Dizdar L; Werner TA; Drusenheimer JC; Möhlendick B; Raba K; Boeck I; Anlauf M; Schott M; Göring W; Esposito I; Stoecklein NH; Knoefel WT; Krieg A
    Int J Cancer; 2019 Mar; 144(6):1379-1390. PubMed ID: 30144031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model.
    Duquette M; Sadow PM; Husain A; Sims JN; Antonello ZA; Fischer AH; Song C; Castellanos-Rizaldos E; Makrigiorgos GM; Kurebayashi J; Nose V; Van Hummelen P; Bronson RT; Vinco M; Giordano TJ; Dias-Santagata D; Pandolfi PP; Nucera C
    Oncotarget; 2015 Dec; 6(40):42445-67. PubMed ID: 26636651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy.
    Klempner SJ; Gershenhorn B; Tran P; Lee TK; Erlander MG; Gowen K; Schrock AB; Morosini D; Ross JS; Miller VA; Stephens PJ; Ou SH; Ali SM
    Cancer Discov; 2016 Jun; 6(6):594-600. PubMed ID: 27048246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring,
    Rossman P; Zabka TS; Ruple A; Tuerck D; Ramos-Vara JA; Liu L; Mohallem R; Merchant M; Franco J; Fulkerson CM; Bhide KP; Breen M; Aryal UK; Murray E; Dybdal N; Utturkar SM; Fourez LM; Enstrom AW; Dhawan D; Knapp DW
    Mol Cancer Ther; 2021 Nov; 20(11):2177-2188. PubMed ID: 34433660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model.
    Danysh BP; Rieger EY; Sinha DK; Evers CV; Cote GJ; Cabanillas ME; Hofmann MC
    Oncotarget; 2016 May; 7(21):30907-23. PubMed ID: 27127178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRAF mutation in papillary thyroid carcinoma: pathogenic role and clinical implications.
    Tang KT; Lee CH
    J Chin Med Assoc; 2010 Mar; 73(3):113-28. PubMed ID: 20230995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MAPK inhibitors induce serine peptidase inhibitor Kazal type 1 (SPINK1) secretion in BRAF V600E-mutant colorectal adenocarcinoma.
    Räsänen K; Dang KX; Mustonen H; Ho TH; Lintula S; Koistinen H; Stenman UH; Haglund C; Stenman J
    Mol Oncol; 2018 Feb; 12(2):224-238. PubMed ID: 29193645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vemurafenib.
    Garbe C; Abusaif S; Eigentler TK
    Recent Results Cancer Res; 2014; 201():215-25. PubMed ID: 24756795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activating FGFR2-RAS-BRAF mutations in ameloblastoma.
    Brown NA; Rolland D; McHugh JB; Weigelin HC; Zhao L; Lim MS; Elenitoba-Johnson KS; Betz BL
    Clin Cancer Res; 2014 Nov; 20(21):5517-26. PubMed ID: 24993163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinct dependencies on receptor tyrosine kinases in the regulation of MAPK signaling between BRAF V600E and non-V600E mutant lung cancers.
    Kotani H; Adachi Y; Kitai H; Tomida S; Bando H; Faber AC; Yoshino T; Voon DC; Yano S; Ebi H
    Oncogene; 2018 Mar; 37(13):1775-1787. PubMed ID: 29348459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.